The American Diabetes Association (ADA), once the undisputed cornerstone of diabetes research and advocacy in the United States, is currently facing an unprecedented existential crisis. A significant coalition of researchers, clinicians, and former organizational leaders has launched a formal boycott against the institution, citing a profound breach of trust, the erosion of academic freedom, and a failure of leadership accountability.
This internal revolt, which continues to gain momentum, centers on the controversial expulsion of five prominent researchers from the organization’s annual Scientific Sessions in New Orleans this past June. The conflict has since metastasized from a dispute over meeting conduct into a battle over the fundamental governance, transparency, and independence of one of the nation’s most influential health nonprofits.
The Genesis of the Conflict: The "New Orleans Five"
The friction began during the ADA’s annual meeting in June, a flagship event that serves as the global stage for advancements in diabetes care. Five researchers—including Dr. Steven Kahn, the editor-in-chief of the ADA’s own prestigious journal, Diabetes Care—were forcibly removed from the conference premises by law enforcement.
The researchers had been distributing an editorial concerning federal funding cuts to diabetes research, a topic central to the mission of the ADA. While the organization initially attempted to frame the ejection as a simple matter of code-of-conduct violations, those involved and their supporters viewed the move as an aggressive attempt to silence dissent and stifle public policy discourse.
In the months following the incident, the relationship between the organization’s executive leadership and its scientific base deteriorated rapidly. The ADA’s refusal to issue a formal apology, coupled with its failure to launch a truly independent investigation as promised by CEO Charles Henderson, prompted the current wave of collective action.
A Chronology of Escalation
The timeline of this institutional collapse reveals a pattern of administrative missteps that have alienated the very experts who give the ADA its scientific credibility.
- June 2024: Five researchers are removed from the ADA Scientific Sessions in New Orleans by security and police for distributing materials regarding federal research funding.
- July 2024: Tensions reach a boiling point when ADA leadership intervenes to block the publication of six opinion pieces and an editorial in Diabetes Care that addressed the June incident.
- Early August 2024: The ADA releases an internal investigation report, claiming the removal of the researchers was unrelated to the content of their materials and strictly a matter of protocol.
- Mid-August 2024: Faced with widespread outcry, the ADA performs an abrupt "about-face," admitting that the audit and governance committee’s findings were incomplete and that the investigation remains ongoing.
- Late August 2024: A formal boycott is launched. Dr. Steven Kahn announces that the editorial team at Diabetes Care will cease handling manuscript submissions until the organization meets their demands for structural reform.
- September 2024: The ADA removes the public notice of the boycott from the journal’s submission portal, a move criticized by leadership as a further attempt to obscure the reality of the crisis from prospective authors.
The Academic "Picket Line"
The most significant blow to the organization’s operational capacity is the refusal of the Diabetes Care editorial team to process new research. By suspending the review of incoming manuscripts, the editors have effectively halted the scientific output of the field’s leading journal.
Dr. Kahn, speaking to MedPage Today, characterized the suspension as an academic picket line. "People who cross the line don’t come out as friends of their friends," he stated, emphasizing the gravity of the decision. The removal of the warning notice from the journal’s website by ADA administrators has only served to deepen the divide, with critics accusing the organization of "muzzling" its members and intentionally misleading potential contributors about the status of their work.
Supporting Data and Stakeholder Sentiment
The scale of the discontent is quantifiable and significant. As of the latest reports, over 400 high-profile individuals—including past ADA presidents, major award winners, and members of the Scientific Sessions committees—have signed the formal boycott pledge.
Beyond the formal boycott, public sentiment remains overwhelmingly critical. A Change.org petition demanding accountability has garnered over 8,000 signatures. Furthermore, a letter signed by more than 500 current and former members has explicitly called for the resignation of CEO Charles Henderson. The signatories demand:
- A transparent, truly independent investigation into the June incident.
- A formal, public apology to the five researchers who were forcibly removed.
- The restoration of total editorial independence for Diabetes Care.
- A comprehensive structural reform of the ADA Board of Directors to ensure it represents the interests of the medical and scientific community rather than solely administrative or political agendas.
Institutional Responses and the "Shifting Justification"
The ADA’s response to the crisis has been widely criticized as inconsistent. Initially, the organization relied on a narrow defense, citing its internal "code of conduct" to justify the actions taken in New Orleans. However, as the scope of the backlash grew, the narrative shifted.
The admission that the initial internal audit was flawed served to undermine the credibility of the Board of Directors. By acknowledging that the investigation did not take into account the "full breadth and depth" of the events, the organization inadvertently confirmed the suspicions of the boycotters: that the internal process was neither comprehensive nor impartial.
In response to the growing unrest, the ADA has promised a final report in the coming weeks. However, for many members, this is "too little, too late." The demand is no longer just for an explanation of the June incident, but for a fundamental shift in how the ADA operates. The boycotters argue that the current leadership has lost its moral authority to steward the organization.
Implications for the Future of Diabetes Advocacy
The implications of this boycott extend far beyond the immediate dispute. The ADA serves as the primary bridge between clinical research and patient care in the United States. A prolonged suspension of Diabetes Care—or a permanent fracture between the organization and its scientific experts—could have tangible consequences for the speed at which life-saving research is disseminated and implemented.
Should the board refuse to meet the demands of the boycotters, the result may be a permanent exodus of talent. Signatories have explicitly stated their intent to align with, or help form, alternative medical societies that prioritize scientific integrity and democratic governance.
For a field as complex and vital as diabetes research, the fragmentation of the premier professional body would be a historic setback. The ADA, an organization tasked with curing a chronic disease, now finds itself suffering from a chronic internal illness of its own making.
Conclusion: The Road to Reconciliation
The path forward is clear, though it may be difficult for an entrenched leadership to follow. The boycott remains active until the board of directors permits an independent, external review of the organization’s structure and function.
As Dr. Kahn noted in his public statements, the ADA’s executive and lay leadership must recognize that reform is not a suggestion—it is a requirement for the continued survival of the organization as a respected scientific entity. The "New Orleans Five" have become a symbol of a broader movement, one that refuses to accept the "muzzling" of science for the sake of institutional convenience.
Whether the American Diabetes Association will choose to evolve through transparency and structural change, or whether it will continue to alienate the very experts it relies upon, remains to be seen. What is certain, however, is that the scientific community has drawn a line in the sand. The era of blind faith in the ADA’s leadership is over; the era of rigorous accountability has begun.
